Healius Limited (HLS.AX)
| Previous close | 3.0200 |
| Open | 3.0300 |
| Bid | 3.0100 x 0 |
| Ask | 2.8800 x 0 |
| Day's range | 2.9950 - 3.0300 |
| 52-week range | 2.5600 - 4.6400 |
| Volume | |
| Avg. volume | 2,816,790 |
| Market cap | 1.76B |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.12 (4.41%) |
| Ex-dividend date | 07 Sept 2022 |
| 1y target est | N/A |
- Business Wire
RingCentral Selected by Healius to Transform Telephony and Contact Center Platform Australia-wide
SYDNEY, Australia & BELMONT, Calif., November 02, 2022--Healius Limited (Healius) (ASX: HLS), one of Australia’s leading healthcare companies, has selected RingCentral, Inc. (NYSE: RNG) to deploy an integrated unified communications as a service (UCaaS) and contact center as a service (CCaaS) solution. This technology investment is designed to improve the doctor and patient experience in Healius’ pathology and diagnostic imaging practices through improvements in communications, initially within
- Business Wire
C2N Diagnostics and Healius Ltd Announce Partnership to Bring PrecivityAD™ and Related Brain Health Biomarkers to Patients in Australia
ST. LOUIS, August 30, 2022--C2N Diagnostics, a leader in advanced brain health diagnostics, and Healius Ltd (ASX:HLS), one of Australia's leading listed healthcare companies, today announced a partnership that will aim to bring C2N’s PrecivityAD™ blood test and related brain health biomarkers to the forefront of memory and dementia care in Australia. The partnership represents C2N’s first international country-wide agreement as it expands its offerings beyond the United States and Europe.
